JP2020514369A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514369A5
JP2020514369A5 JP2019550787A JP2019550787A JP2020514369A5 JP 2020514369 A5 JP2020514369 A5 JP 2020514369A5 JP 2019550787 A JP2019550787 A JP 2019550787A JP 2019550787 A JP2019550787 A JP 2019550787A JP 2020514369 A5 JP2020514369 A5 JP 2020514369A5
Authority
JP
Japan
Prior art keywords
loxl2
antibody
kit
cancer
immunoassay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514369A (ja
Filing date
Publication date
Priority claimed from GBGB1704206.0A external-priority patent/GB201704206D0/en
Application filed filed Critical
Publication of JP2020514369A publication Critical patent/JP2020514369A/ja
Publication of JP2020514369A5 publication Critical patent/JP2020514369A5/ja
Pending legal-status Critical Current

Links

JP2019550787A 2017-03-16 2018-03-14 リシルオキシダーゼ様2アッセイ Pending JP2020514369A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704206.0 2017-03-16
GBGB1704206.0A GB201704206D0 (en) 2017-03-16 2017-03-16 Lysyl oxidase like-2 assay
PCT/EP2018/056364 WO2018167132A1 (en) 2017-03-16 2018-03-14 Lysyl oxidase like-2 assay

Publications (2)

Publication Number Publication Date
JP2020514369A JP2020514369A (ja) 2020-05-21
JP2020514369A5 true JP2020514369A5 (https=) 2021-04-22

Family

ID=58688361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550787A Pending JP2020514369A (ja) 2017-03-16 2018-03-14 リシルオキシダーゼ様2アッセイ

Country Status (5)

Country Link
US (1) US20200123272A1 (https=)
EP (1) EP3596127A1 (https=)
JP (1) JP2020514369A (https=)
GB (1) GB201704206D0 (https=)
WO (1) WO2018167132A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12578335B2 (en) 2020-02-05 2026-03-17 Syntara Limited Bioprobes for lysyl oxidases and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680246B2 (en) * 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
EP2714744A1 (en) 2011-06-01 2014-04-09 Gilead Biologics, Inc. Lysyl oxidase-like 2 assay and methods of use thereof
EP3348576A1 (en) * 2012-10-30 2018-07-18 Gilead Sciences, Inc. Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)

Similar Documents

Publication Publication Date Title
Ferreira et al. DNA aptamers against the MUC1 tumour marker: design of aptamer–antibody sandwich ELISA for the early diagnosis of epithelial tumours
CN103703370B (zh) 诊断性肽的检测
JP2018042573A5 (https=)
JP7022191B2 (ja) 前立腺がんの分析のための組成物及び方法
JP6307509B2 (ja) 腎機能の診断若しくは監視又は腎機能障害の診断方法
JP2013533977A5 (https=)
JP2015533788A5 (https=)
US8900817B2 (en) Progastrin and liver pathologies
US20230184787A1 (en) Calprotectin Assay
JP2014518624A5 (https=)
JP2015514707A5 (https=)
Hong et al. Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials
Vernes et al. Detection and Quantification of VEGF Isoforms by ELISA
JP2020514369A5 (https=)
DK2904398T3 (en) Procedures for predicting the risk of getting cancer in a female individual
JP2021523367A5 (https=)
JP2020514368A5 (https=)
JP2022031783A (ja) APP669-xのN末端を特異的に認識する抗体、及び免疫測定法
JP6317763B2 (ja) 対象における癌となる危険性を予測し又は癌と診断する方法
JP2012521745A5 (https=)
JP2015075395A (ja) 抗NMDAR抗体の各IgGサブクラスの濃度の定量方法
JPWO2019217684A5 (https=)
Tang et al. Development and validation of a magnetic nanoparticle-based chemiluminescent immunoassay for serum surfactant protein D in pulmonary diseases
Guo et al. Ultrasensitive chemiluminescent detection of plasma Aβ1-40 based on soluble macromolecular signal amplification carrier
WO2024107551A1 (en) Novel biomarker and target for treating pulmonary hypertension